Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease that can lead to permanent damage while producing few noticeable symptoms.

Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH.

A kero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects ...

An estimated 1.5% to 6.5% of U.S. adults have MASH. afflicted by the condition, and roughly 24% of adults have metabolic dysfunction-associated steatotic fatty liver disease, the starting point ...

T he Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week. The pill, called ...

The dire current reality Nearly 1 in 4 Americans suffer from metabolic dysfunction–associated steatotic liver disease. Of that population, 20% have the more advanced disease form, MASH.

MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than 40 million people. The results were obtained with a single intramuscular administration of the ...

Conditions That Can Lead to MASLD and MASH Several metabolic problems from high blood pressure to excess body fat can lead to fatty liver disease. But those aren't the only causes. Lesson 3 of 6 ...

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD ...